Jeff Kagy - EPIRUS Biopharmaceutica VP Admin
| EPRSQDelisted Stock | USD 0.0001 0.00 0.00% |
Insider
Jeff Kagy is VP Admin of EPIRUS Biopharmaceuticals
| Phone | 617-600-3497 |
| Web | https://epirusbiopharma.com |
EPIRUS Biopharmaceutica Management Efficiency
The company has return on total asset (ROA) of (0.453) % which means that it has lost $0.453 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.2213) %, meaning that it generated substantial loss on money invested by shareholders. EPIRUS Biopharmaceutica's management efficiency ratios could be used to measure how well EPIRUS Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.EPIRUS Biopharmaceuticals has accumulated 14.85 M in total debt with debt to equity ratio (D/E) of 0.57, which is about average as compared to similar companies. EPIRUS Biopharmaceuticals has a current ratio of 0.77, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist EPIRUS Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, EPIRUS Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like EPIRUS Biopharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for EPIRUS to invest in growth at high rates of return. When we think about EPIRUS Biopharmaceutica's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| MD MSc | Centessa Pharmaceuticals PLC | 64 | |
| Pr MD | Galecto | 69 | |
| Annie MBA | Sutro Biopharma | N/A | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Tia Bush | Centessa Pharmaceuticals PLC | 53 | |
| David MD | Erasca Inc | 40 | |
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| Annie Neild | NewAmsterdam Pharma | N/A | |
| Linda Fitzpatrick | Sutro Biopharma | 67 | |
| Michael Alley | AN2 Therapeutics | N/A | |
| RA MSc | Pharvaris BV | 43 | |
| Behrad Derakhshan | Edgewise Therapeutics | 44 | |
| Joseph Zakrzewski | AN2 Therapeutics | 62 | |
| Jennifer Cormier | PepGen | N/A | |
| Jochen Knolle | Pharvaris BV | 74 | |
| Tim Obara | Genenta Science SpA | N/A | |
| MD MBA | Opthea | N/A | |
| Nicki Vasquez | Sutro Biopharma | 61 | |
| ScD Swartz | Sutro Biopharma | N/A | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| , MBA | Molecular Partners AG | 51 | |
Management Performance
| Return On Equity | -1.22 | |||
| Return On Asset | -0.45 |
EPIRUS Biopharmaceuticals Leadership Team
Elected by the shareholders, the EPIRUS Biopharmaceutica's board of directors comprises two types of representatives: EPIRUS Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EPIRUS. The board's role is to monitor EPIRUS Biopharmaceutica's management team and ensure that shareholders' interests are well served. EPIRUS Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EPIRUS Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Louis Boon, Bioassay CLG | ||
| Jeff Kagy, VP Admin | ||
| Bram Bout, Head BV | ||
| Emile Corven, Head PD | ||
| Jason Yap, Head Director |
EPIRUS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is EPIRUS Biopharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.22 | |||
| Return On Asset | -0.45 | |||
| Operating Margin | (37.45) % | |||
| Current Valuation | (6 M) | |||
| Shares Outstanding | 26.18 M | |||
| Number Of Shares Shorted | 252.54 K | |||
| Price To Earning | (0.01) X | |||
| Price To Book | 0 X | |||
| Price To Sales | 0.0001 X | |||
| Revenue | 701 K |
Pair Trading with EPIRUS Biopharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if EPIRUS Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EPIRUS Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to EPIRUS Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace EPIRUS Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back EPIRUS Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling EPIRUS Biopharmaceuticals to buy it.
The correlation of EPIRUS Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as EPIRUS Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if EPIRUS Biopharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for EPIRUS Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in EPIRUS Pink Sheet
If you are still planning to invest in EPIRUS Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EPIRUS Biopharmaceutica's history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |